WHO WE ARE
Excision BioTherapeutics Inc. is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections.
- We develop gene editing therapies that eradicate or disrupt viral genes in human patients.
- Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
- The company was founded in 2015 and has produced a considerable intellectual property portfolio and therapeutics pipeline covering the use of CRISPR gene editing-based medicines.
MEDIA & PRESS
The Excision BioTherapeutics team includes some of the top biochemistry, chemistry and molecular biology experts with concentrations in the fields of retrovirology, virology, viral genetics, bioinformatics and advanced drug delivery.
AREAS OF FOCUS:
|Human Immunodeficiency Virus-1 Therapeutics|
|JC Virus and Progressive Multifocal Leukoencephalopathy|
|Herpes Simplex Virus 1 and 2 Therapeutics|
|Hepatitis B Virus Therapeutics|
|Advanced DNA and Biologic Delivery Systems|
WHAT PEOPLE ARE SAYING
Researchers find new ways to kick out HIV from Infected Cells
Genome Editing Cuts Out HIV
How Many People Have Been Cured of AIDS
Health: Temple University Researchers Successfully Eliminate HIV Virus in Human Cells
Excision Bio HQ
520 White Plains Rd.
Tarrytown, NY 10591
3624 Market St. #514
Philadelphia, PA 19104
Excision Bio PTY, Ltd.